Aliskiren, an octanamide, is nonpeptide, low molecular weight, orally active renin inhibitor effectively preventing angiotensin and aldosterone release. This drug has been recently approved for the treatment of hypertension. Considering potential links between hypertension, platelets, the coagulation cascade and fibrinolysis we sought to evaluate the effect of aliskiren on human biomarkers of hemostasis. In vitro effects of whole blood preincubation with escalating concentrations of aliskiren (500, 1000 and 2000 ng ml
Introduction
Being a disease with a worldwide prevalence of over 1 billion patients and contributing to 7.1 million deaths per year, arterial hypertension is a major risk factor for cardiovascular mortality throughout the world. 1 Arterial hypertension has been known for centuries; however, effective approaches of its prevention and treatment do not date back more than 50 years. During these last five decades the medical community has witnessed a tremendous evolution in antihypertensive pharmacotherapy, starting off with diuretics 2 and b-blockers 3 the subsequent discovery of angiotensin converting enzyme (ACE) inhibitors and angiotensin receptor blockers, 4, 5 and a concomitant improvement in hypertension control. As long as hypertension has been known as a major risk factor for vascular disease, 6 platelet activation and thrombus formation have also been identified as critical elements in the pathogenesis and natural course of cardiovascular disease and stroke. Conceptually, it may seem somewhat surprising that a condition characterized by hemodynamic vascular stress and abnormal blood flow under high pressure is associated with complications that are most often thrombotic rather than hemorrhagic. 7, 8 In this context, it is noteworthy that several non-antiplatelet drugs diminish platelet function and effectively yield additional clinical benefits in patients with vascular disease, 9, 10 whereas other agents with a pro-thrombotic capacity could be harmful for such patients. 11 Therefore, it is critical that novel antihypertensive drugs not only provide effective control of blood pressure, but also exhibit at least a neutral effect on platelets, coagulation and fibrinolysis.
Aliskiren (SPP100, Tekturna and Rasilez) is a novel blood pressure lowering medication acting as an oral renin inhibitor with an antihypertensive potential that exceeds angiotensin receptor blockers. 12 Its antithrombotic properties remain largely unknown. Considering the above mentioned established links between hypertension and hemostasis, the purpose of this study was to evaluate the effects of aliskiren on biomarkers of platelet function, coagulation and fibrinolysis in vitro in healthy volunteers with multiple cardiovascular risk factors. Moreover, renin per se may directly enhance indices of hemostasis by increasing platelet activity via increase of intraplatelet calcium content, coagulation biomarkers by activating kallikrein-kinin system and blocking plasminogen activator inhibitors (PAIs); therefore, diminishing fibrinolytic capacity. The primary objective of the index study was to indirectly assess potential worsening of vascular outcomes, which are known to be associated with the activation of platelet/coagulation biomarkers and depression of fibrinolysis. On the other hand, we do not want subjects in our study with the preexisting platelet activation, and/or those receiving antithrombotic medications including aspirin. Therefore, healthy subjects with multiple risk factors for the vascular disease represent the best available cohort.
Materials and methods

Subjects
Twenty volunteers donated blood for the study. All of them underwent pre-employment drug screening. Apparently healthy men and women X21 years of age with more than two of the following risk factors such as family history of coronary disease, sedentary lifestyle, diabetes mellitus, hypertension, obesity, hypercholesterolemia, postmenopausal or post-oophorectomied women, or current or recent smoking. Exclusion criteria were a history of bleeding diathesis, stroke, major surgery or significant trauma in the past 6 months; blood pressure 4200/ 110 mm Hg; receiving aspirin or any medications containing aspirin, or any antiplatelet therapy including GPIIb/IIIa inhibitors or thienopyridines within the past 2 weeks; history of platelet count o100 Â 10 9 l À1 or blood dyscrasia. None of these subjects were treated with statins.
Samples
Blood samples were obtained for platelet aggregation, coagulation, fibrinolytic and flow cytometric studies. All subjects underwent blood sampling after at least 30 min of rest and 2 h of fasting. Eight tubes (4.5 ml and containing 3.8% sodium citrate) of blood for a total of 36 ml of whole blood-citrate mixture were collected from each participant between 0800 and 1000 hours to avoid diurnal variations. All specimens were obtained by venipuncture after a 4.5-ml discard sample.
Fresh solutions of aliskiren were prepared ex tempore on the morning during which biomarker studies were performed. Since aliskiren is known to provide a direct effect on renin in plasma, we did not test aliskiren metabolites in our study. Being a small-molecule long-acting renin inhibitor, over 80% of the drug do not bind to plasma proteins, and is eliminated unchanged in urine and feces. Tree tubes were incubated with aliskiren for 60 min at 37 1C to achieve final concentrations of 500, 1000 and 2000 ng ml À1 . Another tube was incubated with buffer solution to serve as an internal control or baseline. The concentration of 500 ng ml À1 is achieved after oral administration 300 mg of aliskiren (steady state C max of 321 ng ml À1 ), whereas the concentration of 2000 ng ml À1 has been selected to test drug safety in a fourfold margin (data on file, Novartis PK&PD division). To avoid possible observer bias, blood samples were coded and blinded. Sampling procedures and biomarker measurements were performed by individuals unaware of the protocol or drug concentration assignment.
Platelet biomarkers Optical aggregation. The whole blood-citrate mixture was centrifuged at 1200 g for 5 min to obtain platelet-rich plasma, which was kept at room temperature for use within 1 h. Platelet counts were determined for each sample with a Coulter Counter ZM (Coulter Co., Hialeah, FL, USA). Platelet numbers were adjusted to 3.50 Â 10 8 ml À1 with homologous platelet-poor plasma. Platelet aggregation was induced by 5 mM adenosine diphosphate and 5 mg ml À1 collagen obtained from Chronolog Corporation (Havertown, PA, USA). Aggregation studies were performed using a 4-channel Chronolog Lumi-Aggregometer (model 560-Ca). Aggregation was expressed as the maximum percentage of light transmittance change (% max) from baseline at the end of the recording time, using platelet-poor plasma as a reference. Aggregation curves were recorded for 6 min and analyzed according to the internationally established standards. 13 Impedance aggregation. The whole blood-citrate mixture was diluted 1:1 with 0.5 ml phosphatebuffered saline and gently swirled. The sample was allowed to warm to 37 1C for 5 min then transferred to the assay well. The electrode was then placed in the cuvette, and platelet aggregation was stimulated with 1 mg ml À1 collagen. The change in electrical impedance was recorded as described previously, that is, utilizing a Chronolog whole blood aggregometer. 14 The ultegra analyzer. The device Accumetrics (San Diego, CA, USA) is a cartridge-based rapid analyzer using adenosine diphosphate as agonist is an optical detection system, which measures platelet-induced aggregation as an increase in light transmittance. When the activated platelets are exposed to the fibrinogen-coated microparticles, agglutination occurs in proportion to the number of available platelet receptors. The whole blood-citrate mixture is being added to the cartridge, and agglutination between platelets and coated beads is being recorded, 15 and the results are reported as platelet activation units. The data mirror turbidometric platelet aggregation and reflect the degree of platelet activity.
PFA-100 analyzer. Using the PFA-100 instrument (Dade Behring Inc., Miami, FL, USA), the bloodcitrate mixture is aspirated under a constant negative pressure and contacts an epinephrine-and collagen-coated membrane. The blood then passes through an aperture that induces high shear stress and simulates primary hemostasis after injury to a small blood vessel under flow condition. The time to aperture occlusion (the closure time) is recorded in seconds and is inversely related to the degree of shear-induced platelet activation. 16 All assays were performed in duplicate. An electronic quality control test was performed on each instrument every day before performing any patient samples.
Flow cytometry. The surface expression of platelet receptors was determined by the whole blood flow cytometry using the following monoclonal antibodies: CD 41 antigen (GP IIb/IIIa), CD 42b (GP Ib), CD 62p (P-selectin), PAC-1 (GP IIb/IIIa activity), CD 31 (platelet/endothelial cell adhesion molecule (PE-CAM)-1), CD 51/CD 61 (vitronectin receptor), CD 63 (LIMP or LAMP-3), CD 107a (LAMP-1), CD154 CD40-ligand), CD 165 (GP37) (PharMingen, San Diego, CA, USA); CD36 (thrombospondin, GPIV), WEDE15 and SPAN12 thrombin receptor epitopes (Beckman Coulter, Brea, CA, USA). Formation of plateletleukocyte aggregates was assessed by dual labeling with pan-platelet marker (CD151), and then with CD14, the macrophage receptor for endotoxin lipopolysaccharides. The blood-citrate mixture (50 ml) was diluted with 450 ml Tris-buffered saline (10 mmol l À1 Tris, 0.15 mol l À1 sodium chloride) and mixed by inverting an Eppendorf tube gently two times. The appropriate primary antibody was then added (5 ml) and incubated at 37 1C for 30 min, and then a secondary antibody was applied if needed. After incubation, 400 ml of 2% buffered paraformaldehyde was added for fixation. The samples were analyzed on a Becton Dickinson FACScan flow cytometer (San Diego, CA, USA) measuring fluorescent light scatter as described previously. 8 All parameters were collected using four-decade logarithmic amplification. The data were collected in list mode files and then analyzed. P-selectin was expressed as percent positive cells as described previously. 17 Other antigens were expressed as log mean fluorescence intensity.
Coagulation biomarkers
Von Willebrand factor was measured by an Asserachrom enzyme-linked immunosorbent assay (Diagnostica Stago Inc., Parsippany, NJ, USA). Antithrombin-III (AT-III) level was determined by the Sta Stachrom-AT III chromogenic substrate assay (Stago). The level of AT-III antigen and total protein S was measured by an immuno-turbidimetric assay (Liatest, Stago); reptilase time, functional protein C and functional protein S was measured by Sta and Staclot clot-based assays (Stago). The quantitative determination of fibrinogen was performed by the Clauss method applying the Sta fibrinogen reagent and Sta analyzers.
Biomarkers of fibrinolysis
Antiplasmin and plasminogen levels were determined by the Sta Stachrom antiplasmin and Stachrom plasminogen chromogenic assays, and fibrinogen degradation products were measured by FDP plasma latex agglutination assays (All Stago).
Statistical analysis
Analysis of variance was used to define significance of differences in biomarkers between baseline and post-aliskiren incubation. The Mann-Whitney U-test was used to analyze nonparametric data. Normally distributed data were expressed as mean±s.e. (m±s.e.), and skewed data as median (range). All P-values were two sided. All analyses were performed using the SPSS v9.0 program (SPSS Inc., Chicago, IL, USA).
Results
Subjects
Demographic data and risk factors are presented in Table 1 . Participants were predominantly Caucasian young-or middle-aged men. Most of the volunteers had a history of smoking and attained to sedentary life style, whereas obesity, disorders of lipid metabolism and family history of vascular disease were less frequent.
Biomarker data
The combined results of platelet, coagulation and fibrinolytic biomarkers when compared with the reference values are summarized in Tables 2 and 3 . Pretreatment of blood samples with the therapeutic aliskiren dose of 500 ng ml À1 resulted in a significant increase of AT-III activity (P ¼ 0.003). All other platelet-coagulation biomarkers were unaffected. Spiking samples with the higher aliskiren concentrations was associated with various counter directed trends in biomarker activity. The 1000 ng ml À1 concentration was associated with some changes of platelet biomarkers suggestive of mild platelet inhibition as measured by decreased adenosine diphosphate-and collagen-induced aggregation, prolongation of the closure time with the PFA-100 Platelet Analyzer, diminished platelet activation units as reflected with the Ultegra Rapid Analyzer, reduction of GP IIb/IIIa activity when measured with a specific PAC-1 antibody and decreased formation of platelet-monocyte aggregates. Incubation of whole blood with aliskiren at 1000 ng ml À1 was not associated with any changes in coagulation biomarkers, with the exception of the consistently increased AT-III activity, which was observed for each tested Aliskiren and biomarkers V Serebruany et al concentration of the renin inhibitor. When testing the 2000 ng ml À1 concentration of the drug there were also some significant changes in platelet-coagulation biomarkers. In contrast to the 1000 ng ml À1 dose, these differences suggested possible mild platelet activation, and reached statistical significance for the Ultegra Analyzer readings, enhanced expression of PECAM-1, GPIb, vitronectin receptor, P-selectin and finally CD63 expression.
Discussion
The present study indicates that the renin-inhibitor aliskiren, independently of the applied dose, consistently activates human AT-III activity in the in vitro setting. In concentrations exceeding twofold therapeutic range, aliskiren provides mild antiplatelet and anticoagulant effects as well; however, these observed changes were random and often divergent, that is, counter-directed, which suggests that they likely do not have any clinical relevance. In addition, since the majority of changes in platelet activity and coagulation were observed far beyond the expected therapeutic concentrations of aliskiren, the clinical significance of these very high doses of aliskiren is limited. Nevertheless, these findings could provide new insights by further defining unknown mechanisms of platelet physiology. Further, they may help achieving a better comprehension of renin-angiotensin's role in the modulation of platelet activity, blood coagulation and clot formation.
The renin-angiotensin-aldosterone system (RAAS) has been identified as one of the major factors in the pathogenesis of most known vascular diseases and their complications. A link between RAAS activation and thrombosis formation also definitely exists. It is known that the RAAS releases its pro-thrombotic potential through the enhanced production of angiotensin II. Appearing within the vasculature, angiotensin II stimulates the release of PAI-1, the major physiological inhibitor of fibrinolysis in vivo, 18 thereby effectively reducing fibrinolytic activity. 19, 20 Angiotensin II also increases the expression of PAI-1 in cultured endothelial and vascular smooth muscle cells. 21, 22 In endothelial cells, the effect of angiotensin II on PAI-1 expression is mediated through its hexapeptide metabolite, angiotensin IV. Thus, the effect of angiotensin II on endothelial PAI-1 expression is not blocked by either angiotensin II type 1 (AT1), or type 2 (AT2) receptor antagonists. The RAAS has been implicated in the proliferative response of the vascular wall after arterial injury, 23 in the synthesis of protooncogenes that are linked to the adaptive process of 24 and in the synthesis of tumor necrosis factor and interleukin-1 by mononuclear cells. 25 ACE converts angiotensin I to angiotensin II and inactivates bradykinin. An increase in ACE activity may impair endothelial function by increasing angiotensin II and accelerating bradykinin degradation. Bradykinin is an endothelium-dependent vasodilator that stimulates the release of nitric oxide (NO), prostacyclin and endothelium-dependent hyperpolarizing factors, classical modulators of hemostasis. Bradykinin is also a potent stimulator for tissue plasminogen activator (t-PA) in endothelial cells. 26 Numerous reports suggest that ACE inhibitors are capable of enhancing fibrinolytic activity through the inhibition of PAI-1 production.
27-29 ACE inhibitors augment t-PA production by coronary arteries in hypertensive patients, 30 and downregulate tissue factor production in monocytes. 31 Besides coagulation hemostasis, the RAAS plays an important role in platelet physiology. 32 Platelet receptor mRNA levels are known to be inversely correlated with plasma angiotensin II levels, whereas mononuclear leukocyte receptor mRNA levels are positively correlated with plasma angiotensin II levels in patients with primary hypertension. 33 In secondary hypertension due to renal artery stenosis, both platelets and mononuclear leucocytes ATII I receptor mRNA are elevated initially, but subsequently decreased after correction of the underlying cause, that is, successful revascularization of the renal artery stenosis. 33 Angiotensin II stimulation significantly increases intracellular platelet calcium concentrations, intracellular pH and thrombin-induced platelet aggregation in untreated hypertensive as well as normotensive individuals. 34 The release of angiotensin II following pro-aggregatory stimulation suggests that this may be one of the mechanisms through which platelets can locally modulate vascular tone and promote atherogenesis. 35 The infusion of angiotensin II increased plasma b-thromboglobulin levels, reflecting a-granule secretion and expression of P-selectin. 36 Several angiotensin receptors blockers demonstrate not profound, but still evident antiplatelet effect. 10, 37, 38 Aliskiren ((2(S),4(S),5(S),7(S)-N-(2-carbamoyl-2-methylpropyl)-5-amino-4-hydroxy-2,7-di-isopropyl-8-[4-methoxy-3-(3-methoxypropoxy)phenyl]-octanamid hemifumarate)), an octanamide, is the first representative of a new class of completely nonpeptide, low molecular weight, orally active transition state renin inhibitors. 39 Aliskiren effectively reduces blood pressure in patients with arterial hypertension 40, 41 regardless of their racial origin, 42 and reduces production of angiotensin I-II in a dosedependent manner. 43 On the basis of our findings, there seems to be no overt perturbation of the hemostatic system upon exposure of the organism to aliskiren. However, it is well established that renin inhibition by aliskiren is accompanied by decrease in angiotensin II levels what itself may indirectly affect the hemostatic system. Other possibilities linking aliskiren and modulation of hemostasis may be due to compliment inhibition, 44 and/or hormonal disturbances. 45 Despite the fact, that in the in vitro setting aliskiren exhibited no pronounced changes in the hemostatic indices, it is possible that in the clinical ex vivo setting, chronic RAAS modulation will be associated with the mild inhibition of platelet activity, 46 coagulation 47 and enhanced fibrinolysis by blocking t-PA and PAI-1. 48 
Limitations
There are a few limitations of the study worth mentioning. We conducted this study in the in vitro setting, and are not drawing any definite clinical conclusions based solely on the index data. Although compatible in size with other similar investigations, this study was performed in a small cohort, so chance represents a plausible alternative explanation. In addition, the expression of multiple activation-dependent platelet receptors was studied but their individual roles are mostly unknown. We are also unaware of any reported data linking aliskiren with the AT-III changes, and cannot presently explain this finding limiting the clinical utility of this study.
Taken together, in the therapeutic concentration of 500 ng ml À1 aliskiren in vitro does not affect hemostatic biomarkers, except for a moderate increase of AT-III activity. Higher aliskiren doses were associated with more profound biomarker changes, but they are likely not to be clinically relevant since they show diverging (that is, both mild antiplatelet and platelet-activating) trends, as well as considering the 2-to 4-fold safety margin. Also, for the future studies, it will be important to expand the research on fibrinolytic indices such as PAI-1 and t-PA, which may be affected by aliskiren.
In conclusion, the moderate but consistent increase of AT-III activity with aliskiren that was observed in our in vitro experiments could be attributed to the chemical compound itself rather than being explained by the immediate modulation of the RAAS system. Therefore, it is suggested that antithrombotic properties of aliskiren be explored further in an ex vivo clinical setting.
